Developing the first FDA-approved treatment for premature ejaculation
We are a clinical-stage life sciences company developing novel therapeutics to address areas of significant unmet need in sexual and mental health.
Our lead and pipeline programs
Kadence Bio is developing its lead asset KH-001 as the first FDA-approved treatment for premature ejaculation (PE), and a pipeline of compounds to target mood disorders. Phase 1 safety studies for KH-001 completed successfully in Q3 2024.
Premature ejaculation at a glance
Hyperconnected societies are on the brink of an ‘intimacy crisis’, with both genders struggling with sexual wellbeing
News
News and Media Coverage
